Merck Commemorates 60th Anniversary of Medical Outreach Program with $300,000 Grant
Merck, known as MSD outside of the U.S. and Canada, announced today that it is offering $300,000 in grants to the non-governmental organization (NGO) partners in the Merck Medical Outreach Program (MMOP) in commemoration of the program’s 60th anniversary. Organizations eligible to apply for funding, up to $60,000 per NGO, are the MMOP’s long standing program partners: Americares, the Catholic Medical Mission Board, Direct Relief, MAP International and Project HOPE. These grants will support the partners’ operations, strengthen capacity building, and improve their supply chain efforts.
“We are proud of Merck’s long history of addressing the needs of underserved populations through the MMOP”, said Brenda Colatrella, Executive Director, Corporate Responsibility at Merck. “Through this grant we are supporting the critical role of our NGO partners in serving under-resourced communities with needed health care assistance.”
Established in 1958, the MMOP is the primary way Merck donates pharmaceuticals and vaccines to benefit people in developing countries, and in support of disaster relief and emergency situations worldwide. The scope of the MMOP varies from year to year and is influenced by changing medical needs in developing countries, the medicines available for donation, and the random nature of disasters. In just the last three years, the MMOP has reached approximately 565,000 people in over 90 countries
Learn more about Merck’s Medical Outreach Program.
Learn more about our company's approach to Corporate Responsibility.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.